HSPA5 and metabolic dysfunction-associated steatotic liver disease: To evaluate which of the two proteins is more likely to be a potential target for lycorine therapy for MASLD, we performed western blot, and the results confirmed that the protein expression of HSPA5 was not significantly different between the groups (Fig. 4C).